Sunshine Biopharma Inc. (NASDAQ: SBFM) has closed its previously announced public offering, generating approximately $6 million in gross proceeds before fees and expenses. The company sold 12 million common units, each consisting of either one share of common stock or one pre-funded warrant, along with two Series C warrants. Aegis Capital Corp. acted as the exclusive placement agent for the offering.
According to the company, net proceeds from the offering will be used for general corporate purposes and working capital. Additionally, if the Series C warrants are fully exercised for cash, the company could receive up to approximately $12 million in additional gross proceeds. The warrants have an exercise price of $0.75 per share and are exercisable immediately, expiring five years from the date of issuance.
Sunshine Biopharma currently markets 60 generic prescription drugs in Canada and has plans to launch 12 additional generic products during the remainder of 2026. The company is also advancing two proprietary drug development programs: K1.1 mRNA, an mRNA-Lipid Nanoparticle therapeutic candidate targeting liver cancer, and a PLpro protease inhibitor, a small-molecule antiviral candidate for SARS-related coronavirus infections. More information is available at https://sunshinebiopharma.com/.
The closing of this offering provides Sunshine Biopharma with additional capital to support its ongoing operations and research initiatives. The company's dual focus on expanding its generic drug portfolio and developing novel therapeutics positions it to address both immediate market needs and long-term opportunities in oncology and infectious diseases.
Aegis Capital Corp. served as the exclusive placement agent, and the offering was made pursuant to an effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission. The full press release is available at https://ibn.fm/XuHPC.
This financing event is a critical milestone for Sunshine Biopharma as it seeks to strengthen its balance sheet and accelerate its pipeline. The proceeds will enable the company to continue its generic drug launches in Canada while advancing its proprietary drug development programs. The potential additional funds from warrant exercises could further bolster the company's financial flexibility.
Sunshine Biopharma's strategy of combining a stable generic revenue stream with high-potential proprietary drug development is designed to mitigate risk while maximizing upside. The company's focus on liver cancer and coronavirus infections addresses significant unmet medical needs. The successful closing of this offering underscores investor confidence in the company's direction and management team.
For more information about Sunshine Biopharma and its programs, visit the company's website. This announcement highlights the company's commitment to delivering value to shareholders while advancing healthcare solutions.